Literature DB >> 1455886

Prostacyclin release from the human saphenous vein in diabetics in lower than in nondiabetics.

J S Brunkwall1, D Bergqvist.   

Abstract

The balance between prostacyclin and thromboxane has been suggested to be of great importance for the maintenance of patency in veins. In order to investigate prostacyclin and thromboxane release, segments from the human saphenous veins were investigated in 53 patients. Twenty-seven patients (10 males, 17 females) underwent surgery for varicose veins. Twenty-six patients (14 nondiabetics, 12 diabetics) underwent surgery for lower limb ischemia (rest pain or gangrene) with use of the saphenous vein as arterial conduit. Vein segments were gently excised and perfused ex vivo for five 15 minute periods, with a balanced salt solution and determination of the stable degradation products 6-keto-PGF1 alpha and TxB2. Saphenous veins from patients with varicose veins had an initial prostacyclin release of 61 +/- 13 pg/mm2/15 min declining to 4 +/- 1 pg/mm2/15 min after 60 min (p < 0.001) and increasing after addition to arachidonic acid to 37 +/- 7 pg/mm2/15 min (p < 0.001). Segments from nondiabetic patients with lower limb ischemia did not differ from those of varicectomy patients, but diabetic segments had a significantly lower prostacyclin release than both these groups, 34 +/- 11 pg/mm2/15 min, 1 +/- 1 pg/mm2/15 min, and 7 +/- 5 pg/mm2/15 min, respectively (p < 0.05). The addition of arachidonic acid failed to increase the prostacyclin release in diabetics. Three patients from each group were studied regarding thromboxane release and there was almost no detectable thromboxane in any group. These findings suggest that diabetics have a lowered prostacyclin release from the saphenous vein and that the deficiency is at the cyclo-oxygenase level.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1455886     DOI: 10.1007/bf02067081

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  25 in total

1.  Influence of pressure, flow rate, and pulsatility on release of 6-keto-PGF1 alpha and thromboxane B2 in ex vivo-perfused canine veins.

Authors:  J S Brunkwall; J C Stanley; L M Graham; W E Burkel
Journal:  J Vasc Surg       Date:  1988-01       Impact factor: 4.268

2.  Comparison of static incubation versus physiologic perfusion techniques for quantitation of luminal release of prostacyclin and thromboxane in canine arteries and veins.

Authors:  J S Brunkwall; J C Stanley; L M Graham; W E Burkel; D Bergqvist
Journal:  J Surg Res       Date:  1988-07       Impact factor: 2.192

3.  An imbalance in arachidonic acid metabolism in diabetes.

Authors:  M Johnson; A H Reece; H E Harrison
Journal:  Adv Prostaglandin Thromboxane Res       Date:  1980

4.  Arterial 6-keto-PGF1 alpha and TxB2 release in ex vivo perfused canine vessels: effects of pulserate, pulsatility, altered pressure and flow rate.

Authors:  J S Brunkwall; J C Stanley; L M Graham; W E Burkel; D Bergqvist
Journal:  Eur J Vasc Surg       Date:  1989-06

5.  Prostanoid production in varicose veins: evidence for decreased prostacyclin with increased thromboxane A2 and prostaglandin E2 formation.

Authors:  G Biagi; A Lapilli; R Zendron; L Piccinni; S Coccheri
Journal:  Angiology       Date:  1988-12       Impact factor: 3.619

6.  Postoperative deep venous thrombosis after renal transplantation. Effects of cyclosporine.

Authors:  J Brunkwall; D Bergqvist; S E Bergentz; S Bornmyr; B Husberg
Journal:  Transplantation       Date:  1987-05       Impact factor: 4.939

7.  Plasma 6-keto-PGF1 alpha, thromboxane B2 and PGE2 in type 1 (insulin-dependent) diabetic patients during exercise.

Authors:  T Mourits-Andersen; I W Jensen; P N Jensen; J Ditzel; J Dyerberg
Journal:  Diabetologia       Date:  1987-07       Impact factor: 10.122

8.  Variables associated with postoperative deep venous thrombosis: a prospective study of 411 gynecology patients and creation of a prognostic model.

Authors:  D L Clarke-Pearson; E R DeLong; I S Synan; R E Coleman; W T Creasman
Journal:  Obstet Gynecol       Date:  1987-02       Impact factor: 7.661

9.  Vascular prostacyclin, platelet sensitivity to prostaglandins and platelet-specific proteins in diabetes mellitus. Analysis of type of diabetes, state of metabolic control and diabetic microangiopathy.

Authors:  G Schernthaner; H Sinzinger; K Silberbauer; H Freyler; I Mühlhauser; J Kaliman
Journal:  Horm Metab Res Suppl       Date:  1981

10.  The effect of unfractionated and low-molecular-weight heparin on the release of prostacyclin from the arterial wall.

Authors:  J Brunkwall; T Mätzsch; D Bergqvist
Journal:  Blood Coagul Fibrinolysis       Date:  1990-12       Impact factor: 1.276

View more
  2 in total

1.  The potential contribution of endothelin-1 to neurovascular abnormalities in streptozotocin-diabetic rats.

Authors:  N E Cameron; K C Dines; M A Cotter
Journal:  Diabetologia       Date:  1994-12       Impact factor: 10.122

2.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.